On February 19, Stryker officially announced the completion of its acquisition of Inari Medical. Previously, Stryker had announced a deal worth $4.9 billion (equivalent to 36 billion RMB) aimed at acquiring this company, which focuses on the treatment of venous thromboembolism (VTE).

Stryker stated that the acquisition of Inari Medical will establish the company's position in the rapidly growing VTE field within peripheral vascular solutions. This move will not only further expand Stryker’s product portfolio but also mark a significant breakthrough in its interventional endovascular product offerings.

In January, Patterson Companies, the global leader in dental instruments, announced that it had reached a definitive agreement to be acquired by private equity firm Patient Square Capital. According to Dow Jones Market Data, the deal, valued at approximately $4.1 billion (RMB 29.9 billion), drove Patterson's stock price up by 34.36% to $31.10, marking the largest single-day gain in its trading history.

February 25,Thermo Fisher Scientific announced a major acquisition plan. The company will acquire Solventum's purification and filtration business for $4.1 billion (approximately RMB 29.8 billion) in cash. This news has drawn strong attention from the capital market.

Data shows that Solventum was spun off from 3M Company and independently listed last year. Its purification and filtration business holds key technologies in the fields of medical technology, biotechnology, and industrial applications, providing significant support for the production of related products. In 2024, this business generated approximately $1 billion in revenue, demonstrating strong market potential.

On January 28, Zimmer Biomet announced that it had reached a definitive agreement with Paragon 28, Inc. to acquire all outstanding common shares of Paragon 28 for a cash upfront payment of $XX per share, representing a total value of approximately $1.2 billion (approximately 8.7 billion RMB). The transaction is expected to be completed in the first half of this year.

Zimmer Biomet President and CEO Ivan Tornos stated that this proposed transaction diversifies Zimmer Biomet's portfolio beyond core orthopedics and positions it advantageously in the fastest-growing specialties within the musculoskeletal care field, while also creating cross-selling opportunities in the rapidly expanding ASC (Ambulatory Surgery Center) sector.

On January 8, Boston Scientific Corporation announced,Boston Scientific Corporation has reached a definitive acquisition agreement with Bolt Medical, Inc. The transaction includes an upfront payment of approximately $443 million for the acquisition of 74% of Bolt Medical's shares, along with up to $221 million in payments upon the achievement of milestones.

Bolt Medical is a company that develops advanced laser-based intravascular lithotripsy (IVL) platforms for the treatment of coronary and peripheral artery diseases. Boston Scientific initially developed the concept of the Bolt IVL system and, as a strategic investor in Bolt Medical, holds approximately 26% equity. On April 2, Boston Scientific announced the completion of its acquisition of Bolt Medical.

On March 3, medical device giant Boston Scientific announced a major acquisition plan. The company has reached an agreement to acquire SoniVie, a developer of intravascular ultrasound systems. The total value of this transaction is $600 million (approximately RMB 4.4 billion).

This company has developed the TIVUS intravascular ultrasound system. The TIVUS system is an experimental technology designed to treat various hypertensive disorders by performing denervation of perivascular nerves, including renal artery denervation (RDN) for hypertension.

On January 6, 2025, Hologic announced the completion of its acquisition of Gynesonics. Hologic announced in October that it would acquire Gynesonics for $350 million (equivalent to over 2.5 billion RMB).

Gynesonics' Sonata System is the first and only diagnostic intrauterine imaging device approved by the U.S. Food and Drug Administration (FDA) for transcervical treatment of specific symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation through a minimally invasive procedure.